TriangleStudy reference · NCT04035486
FLAURA2
Adding chemotherapy to osimertinib: final overall survival
Fixed release · explorer-2026-09-11At four years, estimated overall survival was 49.1% with osimertinib plus chemotherapy and 40.8% with osimertinib alone. Severe adverse events were more frequent with the combination.
Estimated survival at 4 years
Overall survival · percentage alive in each trial group
The small black line shows uncertainty (95% confidence interval), where available. These estimates describe study groups, not an individual’s chance of survival.
Overall-survival hazard ratio: 0.77 (95% CI 0.61–0.96), combination versus osimertinib alone.
Grade 3 or higher adverse events from any cause
Final overall-survival report. Lower percentages mean fewer reported severe events.
Safety results as reported for treated participants; safety denominators are not independently verified in this preview.
Put the research in context
Who was studied?
Compare the reported population with what you know. It is fine to be unsure—those are useful questions for your care team.
Read the original sources →These are reported population details, not a complete list of eligibility criteria. Who could enroll, who participated, and whose results were analyzed can differ. This checklist does not score your match, recommend treatment, or determine trial eligibility.
Your selections and question stay on this page only. They are not saved or sent to Triangle. Copy your note before leaving; refreshing clears it.
Keep your next appointment in mind.
Copy your question, then sign in to Triangle.
This note is not transferred automatically.
Study design & endpoints
Open-label, randomized phase 3 trial; 557 participants.
Primary: progression-free survival. Overall survival was a key secondary endpoint; this is its planned final analysis.
What the chart cannot tell you
- The combination included platinum and pemetrexed chemotherapy, followed by maintenance treatment.
- Four-year landmark percentages and their confidence intervals come from the sponsor’s published results table, separately identified below.
- Severe adverse events include events from any cause. Quality-of-life results are not included in this preview.
Results are group estimates, not a personalized forecast, treatment recommendation, or confirmation of trial eligibility.
Full results table
| Group | Efficacy n | Median overall survival, months (CI) | Survival at 4 years (95% CI) | Severe events |
|---|---|---|---|---|
| Osimertinib + chemotherapy | 279 | 47.5 (41.0–not calculable) | 49.1% (43–55%) | 70% |
| Osimertinib alone | 278 | 37.6 (33.2–43.2) | 40.8% (34.9–46.6%) | 34% |
Grade 3 or higher adverse events from any cause. Safety results as reported for treated participants; safety denominators are not independently verified in this preview.
Median survival is a time point, not average lifespan. Confidence levels and analysis details are reported with the source.